Alignment Healthcare (NASDAQ:ALHC) Stock Price Target Cut by Barclays

Alignment Healthcare (NASDAQ:ALHC) had its price target reduced by analysts at Barclays from $10.00 to $9.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Barclays‘s price objective points to a potential upside of 15.46% from the company’s current price.

Other equities research analysts also recently issued reports about the company. UBS Group lowered their price target on Alignment Healthcare from $22.00 to $9.00 and set a “neutral” rating for the company in a report on Monday, October 12th. Zacks Research lowered Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Wall Street Zen cut Alignment Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. JPMorgan Chase & Co. dropped their target price on shares of Alignment Healthcare from $22.00 to $10.00 and set an “overweight” rating on the stock in a report on Friday, October 9th. Finally, KeyCorp cut shares of Alignment Healthcare from an “overweight” rating to a “sector weight” rating in a report on Friday. Six investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $15.82.

Alignment Healthcare Stock Performance

Alignment Healthcare stock opened at $7.79 on Friday. The stock has a fifty day moving average price of $9.99 and a two-hundred day moving average price of $16.89. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.70. Alignment Healthcare has a 52-week low of $6.01 and a 52-week high of $25.12. The firm has a market capitalization of $1.62 billion, a P/E ratio of 41.34 and a beta of 1.14.

Alignment Healthcare (NASDAQ:ALHC) last released its quarterly earnings results on Thursday, October 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04). The business had revenue of $1.36 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Alignment Healthcare had a return on equity of 20.02% and a net margin of 0.89%. The firm’s revenue for the quarter was up 36.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.02 earnings per share. As a group, analysts anticipate that Alignment Healthcare will post 0.14 EPS for the current fiscal year.

Insider Transactions at Alignment Healthcare

In other news, insider Hyong Kim sold 32,479 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $8.30, for a total value of $269,575.70. Following the completion of the sale, the insider owned 299,271 shares of the company’s stock, valued at approximately $2,483,949.30. The trade was a 9.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John E. Kao sold 385,270 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $12.68, for a total transaction of $4,885,223.60. Following the transaction, the chief executive officer owned 1,223,473 shares in the company, valued at approximately $15,513,637.64. The trade was a 23.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 1,061,967 shares of company stock worth $13,642,490 over the last three months. Company insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Alignment Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oregon Public Employees Retirement Fund grew its holdings in shares of Alignment Healthcare by 11.7% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 41,900 shares of the company’s stock worth $342,000 after purchasing an additional 4,400 shares in the last quarter. Vise Technologies Inc. raised its stake in Alignment Healthcare by 31.2% in the third quarter. Vise Technologies Inc. now owns 12,163 shares of the company’s stock valued at $99,000 after purchasing an additional 2,894 shares in the last quarter. VestGen Advisors LLC acquired a new position in Alignment Healthcare in the third quarter valued at about $135,000. Park Avenue Securities LLC raised its stake in Alignment Healthcare by 37.2% in the third quarter. Park Avenue Securities LLC now owns 59,635 shares of the company’s stock valued at $487,000 after purchasing an additional 16,157 shares in the last quarter. Finally, Sterling Capital Management LLC lifted its position in Alignment Healthcare by 839.9% during the third quarter. Sterling Capital Management LLC now owns 6,739 shares of the company’s stock worth $55,000 after purchasing an additional 6,022 shares during the period. 86.19% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Third-quarter revenue increased 36.7% year over year to $1.36 billion, exceeding the $1.31 billion analyst consensus. The company’s quarterly loss of $0.04 per share was in line with expectations. Alignment Healthcare Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: Management is targeting at least 20% top-line growth in 2027, signaling continued membership and revenue expansion potential. Alignment Targets 2027 Top-Line Growth
• Neutral Sentiment: KeyCorp downgraded Alignment Healthcare from “overweight” to “sector weight,” indicating a less favorable risk-reward view but not an outright sell recommendation. KeyCorp Analyst Ratings
• Negative Sentiment: Alignment lowered its 2026 adjusted EBITDA outlook to at least $100 million. Although the company maintained a growth outlook, the guidance change raises concerns about near-term margins, earnings quality, and execution. Alignment Healthcare Third-Quarter Results and Updated Outlook
• Negative Sentiment: Two law firms announced investigations into potential securities-law violations, including allegations related to possibly inflated EBITDA disclosures. These announcements may add reputational and legal-risk overhang, although they do not establish wrongdoing. Block and Leviton Alignment Healthcare Investigation BFA Law Alignment Healthcare Investigation

Alignment Healthcare Company Profile

Alignment Healthcare, Inc is a technology-enabled health insurance company focused on providing Medicare Advantage plans for seniors. The company combines health plan coverage with care coordination and clinical services designed to help members manage chronic conditions, access providers and navigate the health care system.

Its offerings include Medicare Advantage plans, supplemental benefits and member support services. Alignment also uses its proprietary technology platform, including the Alignment Virtual Application (AVA), to support care teams, analyze health information and help deliver more personalized services to members.

Founded in 2013, Alignment Healthcare serves Medicare-eligible consumers in selected markets, including California, Florida, Nevada and North Carolina.